GSK announced that the US FDA has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli alone, to treat adult patients with primary or recurrent advanced endometrial cancer.

This expanded approval now includes patients with MMRp/MSS tumors, representing 70-75% of endometrial cancer cases with few treatment options.

Approval is based on significant overall and progression-free survival results from a Phase III clinical trial showing a 31% reduction in the risk of death compared with chemotherapy alone.

Common side effects include nausea, fatigue and peripheral neuropathy. This approval provides a new treatment option to improve outcomes for patients with this type of cancer.

Copyright (c) 2024 CercleFinance.com. All rights reserved.